
GeoVax Advances in Vaccine and Immunotherapy Development with Promising Clinical Data
GeoVax Labs reports significant progress in its vaccine and immunotherapy programs, including favorable European regulatory guidance for GEO-MVA and robust immune responses from GEO-CM04S1 in CLL patients, highlighting the company's potential to address urgent medical needs.
Read full story
























